Do analysts recommend PETV or FEMY?

Femasys has a consensus target price of $56.67, indicating a potential upside of 2,374.53%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, PETV or FEMY?

PetVivo has higher earnings, but lower revenue than Femasys. PetVivo is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PetVivo $1.05M 24.67 -$10.95M -$0.38 N/A Femasys $2.29M 3.02 -$18.63M -$5.40 N/A

Is PETV or FEMY more profitable?

Femasys has a net margin of -521.97% compared to PetVivo's net margin of -902.82%. Femasys' return on equity of -258.08% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets PetVivo -902.82% -4,813.07% -281.78% Femasys -521.97% -258.08% -73.72%

Does the media prefer PETV or FEMY?

In the previous week, Femasys had 11 more articles in the media than PetVivo. MarketBeat recorded 13 mentions for Femasys and 2 mentions for PetVivo. Femasys' average media sentiment score of 1.10 beat PetVivo's score of 0.00 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Femasys 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, FEMY or CTSO?

Cytosorbents has higher revenue and earnings than Femasys. Cytosorbents is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 3.02 -$18.63M -$5.40 N/A Cytosorbents $37.06M 0.68 -$8.20M -$0.29 N/A

Is FEMY or CTSO more profitable?

Cytosorbents has a net margin of -48.94% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Cytosorbents' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% Cytosorbents -48.94% -309.53% -40.60%

Does the media refer more to FEMY or CTSO?

In the previous week, Cytosorbents had 1 more articles in the media than Femasys. MarketBeat recorded 14 mentions for Cytosorbents and 13 mentions for Femasys. Femasys' average media sentiment score of 1.10 beat Cytosorbents' score of -0.47 indicating that Femasys is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytosorbents 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, FEMY or LFWD?

Femasys has higher earnings, but lower revenue than Lifeward. Femasys is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 3.02 -$18.63M -$5.40 N/A Lifeward $20.92M 1.01 -$19.91M -$19.66 N/A

Is FEMY or LFWD more profitable?

Lifeward has a net margin of -123.66% compared to Femasys' net margin of -521.97%. Lifeward's return on equity of -243.14% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -521.97% -258.08% -73.72% Lifeward -123.66% -243.14% -97.39%

Does the media refer more to FEMY or LFWD?

In the previous week, Femasys had 7 more articles in the media than Lifeward. MarketBeat recorded 13 mentions for Femasys and 6 mentions for Lifeward. Femasys' average media sentiment score of 1.10 beat Lifeward's score of 0.62 indicating that Femasys is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifeward 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend FEMY or ZJYL?

Femasys presently has a consensus price target of $56.67, indicating a potential upside of 2,374.53%. Given Femasys' stronger consensus rating and higher possible upside, equities research analysts plainly believe Femasys is more favorable than Jin Medical International. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Jin Medical International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, FEMY or ZJYL?

Jin Medical International has higher revenue and earnings than Femasys. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Femasys $2.29M 3.02 -$18.63M -$5.40 N/A Jin Medical International $19.73M 1.17 $1.19M N/A N/A

Does the media refer more to FEMY or ZJYL?

In the previous week, Femasys had 10 more articles in the media than Jin Medical International. MarketBeat recorded 13 mentions for Femasys and 3 mentions for Jin Medical International. Jin Medical International's average media sentiment score of 1.12 beat Femasys' score of 1.10 indicating that Jin Medical International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jin Medical International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ADGM or FEMY?

Femasys has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagio Medical $600K 25.62 -$25.08M -$1.53 N/A Femasys $2.29M 3.02 -$18.63M -$5.40 N/A

Is ADGM or FEMY more profitable?

Adagio Medical has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Adagio Medical's return on equity. Company Net Margins Return on Equity Return on Assets Adagio Medical N/A -484.14% -71.34% Femasys -521.97% -258.08% -73.72%

Does the media prefer ADGM or FEMY?

In the previous week, Femasys had 9 more articles in the media than Adagio Medical. MarketBeat recorded 13 mentions for Femasys and 4 mentions for Adagio Medical. Femasys' average media sentiment score of 1.10 beat Adagio Medical's score of -0.28 indicating that Femasys is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adagio Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Femasys 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Femasys (FEMY) Competitors

$2.29 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.26 -0.03 (-1.44%)

As of 07:55 PM Eastern

Compare

FEMY vs. PETV, CTSO, LFWD, ZJYL, and ADGM

Should you buy Femasys stock or one of its competitors? Femasys's main competitors and comparable companies include PetVivo (PETV), Cytosorbents (CTSO), Lifeward (LFWD), Jin Medical International (ZJYL), and Adagio Medical (ADGM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Femasys compare to PetVivo?

PetVivo (NASDAQ:PETV) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Femasys has a net margin of -521.97% compared to PetVivo's net margin of -902.82%. Femasys' return on equity of -258.08% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PetVivo	-902.82%	-4,813.07%	-281.78%
Femasys	-521.97%	-258.08%	-73.72%

In the previous week, Femasys had 11 more articles in the media than PetVivo. MarketBeat recorded 13 mentions for Femasys and 2 mentions for PetVivo. Femasys' average media sentiment score of 1.10 beat PetVivo's score of 0.00 indicating that Femasys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Femasys has a consensus target price of $56.67, indicating a potential upside of 2,374.53%. Given Femasys' stronger consensus rating and higher probable upside, analysts clearly believe Femasys is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

PetVivo has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Femasys has a beta of -2.08, indicating that its stock price is 308% less volatile than the broader market.

PetVivo has higher earnings, but lower revenue than Femasys. PetVivo is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PetVivo	$1.05M	24.67	-$10.95M	-$0.38	N/A
Femasys	$2.29M	3.02	-$18.63M	-$5.40	N/A

24.5% of PetVivo shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 10.8% of PetVivo shares are held by insiders. Comparatively, 7.8% of Femasys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Femasys beats PetVivo on 11 of the 16 factors compared between the two stocks.

How does Femasys compare to Cytosorbents?

Femasys (NASDAQ:FEMY) and Cytosorbents (NASDAQ:CTSO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Femasys presently has a consensus price target of $56.67, indicating a potential upside of 2,374.53%. Cytosorbents has a consensus price target of $5.38, indicating a potential upside of 1,244.09%. Given Femasys' stronger consensus rating and higher probable upside, equities research analysts clearly believe Femasys is more favorable than Cytosorbents.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cytosorbents has higher revenue and earnings than Femasys. Cytosorbents is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	3.02	-$18.63M	-$5.40	N/A
Cytosorbents	$37.06M	0.68	-$8.20M	-$0.29	N/A

In the previous week, Cytosorbents had 1 more articles in the media than Femasys. MarketBeat recorded 14 mentions for Cytosorbents and 13 mentions for Femasys. Femasys' average media sentiment score of 1.10 beat Cytosorbents' score of -0.47 indicating that Femasys is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytosorbents	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cytosorbents has a net margin of -48.94% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Cytosorbents	-48.94%	-309.53%	-40.60%

Femasys has a beta of -2.08, suggesting that its share price is 308% less volatile than the broader market. Comparatively, Cytosorbents has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

65.3% of Femasys shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 7.8% of Femasys shares are held by company insiders. Comparatively, 7.8% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Femasys and Cytosorbents tied by winning 8 of the 16 factors compared between the two stocks.

How does Femasys compare to Lifeward?

Femasys (NASDAQ:FEMY) and Lifeward (NASDAQ:LFWD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Femasys had 7 more articles in the media than Lifeward. MarketBeat recorded 13 mentions for Femasys and 6 mentions for Lifeward. Femasys' average media sentiment score of 1.10 beat Lifeward's score of 0.62 indicating that Femasys is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifeward	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifeward has a net margin of -123.66% compared to Femasys' net margin of -521.97%. Lifeward's return on equity of -243.14% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Lifeward	-123.66%	-243.14%	-97.39%

Femasys has higher earnings, but lower revenue than Lifeward. Femasys is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	3.02	-$18.63M	-$5.40	N/A
Lifeward	$20.92M	1.01	-$19.91M	-$19.66	N/A

Femasys has a beta of -2.08, meaning that its share price is 308% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

Femasys currently has a consensus target price of $56.67, indicating a potential upside of 2,374.53%. Lifeward has a consensus target price of $10.00, indicating a potential upside of 34.23%. Given Femasys' stronger consensus rating and higher possible upside, equities analysts clearly believe Femasys is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Lifeward	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

65.3% of Femasys shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 7.8% of Femasys shares are owned by insiders. Comparatively, 1.5% of Lifeward shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Femasys beats Lifeward on 11 of the 16 factors compared between the two stocks.

How does Femasys compare to Jin Medical International?

Femasys (NASDAQ:FEMY) and Jin Medical International (NASDAQ:ZJYL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Jin Medical International has higher revenue and earnings than Femasys.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	3.02	-$18.63M	-$5.40	N/A
Jin Medical International	$19.73M	1.17	$1.19M	N/A	N/A

Femasys presently has a consensus price target of $56.67, indicating a potential upside of 2,374.53%. Given Femasys' stronger consensus rating and higher possible upside, equities research analysts plainly believe Femasys is more favorable than Jin Medical International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Jin Medical International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Femasys had 10 more articles in the media than Jin Medical International. MarketBeat recorded 13 mentions for Femasys and 3 mentions for Jin Medical International. Jin Medical International's average media sentiment score of 1.12 beat Femasys' score of 1.10 indicating that Jin Medical International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jin Medical International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Femasys has a beta of -2.08, meaning that its share price is 308% less volatile than the broader market. Comparatively, Jin Medical International has a beta of 7.34, meaning that its share price is 634% more volatile than the broader market.

Jin Medical International has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Jin Medical International's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Jin Medical International	N/A	N/A	N/A

65.3% of Femasys shares are owned by institutional investors. 7.8% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Femasys and Jin Medical International tied by winning 7 of the 14 factors compared between the two stocks.

How does Femasys compare to Adagio Medical?

Adagio Medical (NASDAQ:ADGM) and Femasys (NASDAQ:FEMY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Adagio Medical has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat Adagio Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	-484.14%	-71.34%
Femasys	-521.97%	-258.08%	-73.72%

Femasys has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagio Medical	$600K	25.62	-$25.08M	-$1.53	N/A
Femasys	$2.29M	3.02	-$18.63M	-$5.40	N/A

Adagio Medical has a beta of -0.15, indicating that its stock price is 115% less volatile than the broader market. Comparatively, Femasys has a beta of -2.08, indicating that its stock price is 308% less volatile than the broader market.

Adagio Medical presently has a consensus target price of $3.50, indicating a potential upside of 405.63%. Femasys has a consensus target price of $56.67, indicating a potential upside of 2,374.53%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Adagio Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Femasys had 9 more articles in the media than Adagio Medical. MarketBeat recorded 13 mentions for Femasys and 4 mentions for Adagio Medical. Femasys' average media sentiment score of 1.10 beat Adagio Medical's score of -0.28 indicating that Femasys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagio Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.1% of Adagio Medical shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 7.8% of Adagio Medical shares are held by company insiders. Comparatively, 7.8% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Femasys beats Adagio Medical on 10 of the 16 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEMY vs. The Competition

Export

Metric	Femasys	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.92M	$5.80B	$6.98B	$13.04B
Dividend Yield	N/A	1.76%	2.58%	10.72%
P/E Ratio	-0.42	26.26	269.86	25.30
Price / Sales	3.02	40.09	601.81	101.06
Price / Cash	N/A	33.59	70.53	50.75
Price / Book	1.14	5.91	13.08	6.33
Net Income	-$18.63M	$148.67M	$3.45B	$347.70M
7 Day Performance	-13.91%	1.84%	1.12%	1.07%
1 Month Performance	-36.39%	4.56%	1.79%	1.03%
1 Year Performance	-84.58%	8.67%	67.69%	20.77%

Femasys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEMY Femasys	3.2912 of 5 stars	$2.29 flat	$56.67 +2,374.5%	-85.1%	$6.92M	$2.29M	N/A	30	Positive News Earnings Report Analyst Forecast
PETV PetVivo	N/A	$0.72 +4.7%	N/A	-16.3%	$27.42M	$1.05M	N/A	20	News Coverage
CTSO Cytosorbents	1.7644 of 5 stars	$0.36 -0.6%	$5.38 +1,393.1%	-66.5%	$22.62M	$37.06M	N/A	220	News Coverage Analyst Revision
LFWD Lifeward	2.276 of 5 stars	$7.59 -1.6%	$10.00 +31.8%	-8.3%	$21.45M	$20.92M	N/A	60	News Coverage Earnings Report
ZJYL Jin Medical International	1.3273 of 5 stars	$2.98 +2.1%	N/A	-74.9%	$20.35M	$20.69M	N/A	245	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEMY) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Femasys (FEMY) Competitors

FEMY vs. PETV, CTSO, LFWD, ZJYL, and ADGM

How does Femasys compare to PetVivo?

Summary

How does Femasys compare to Cytosorbents?

Summary

How does Femasys compare to Lifeward?

Summary

How does Femasys compare to Jin Medical International?

Summary

How does Femasys compare to Adagio Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Femasys (FEMY) Competitors

FEMY vs. PETV, CTSO, LFWD, ZJYL, and ADGM

How does Femasys compare to PetVivo?

Is PETV or FEMY more profitable?

Does the media prefer PETV or FEMY?

Do analysts recommend PETV or FEMY?

Which has more volatility and risk, PETV or FEMY?

Which has preferable earnings and valuation, PETV or FEMY?

Do institutionals & insiders believe in PETV or FEMY?

Summary

How does Femasys compare to Cytosorbents?

Do analysts prefer FEMY or CTSO?

Which has preferable earnings & valuation, FEMY or CTSO?

Does the media refer more to FEMY or CTSO?

Is FEMY or CTSO more profitable?

Which has more volatility and risk, FEMY or CTSO?

Do institutionals and insiders believe in FEMY or CTSO?

Summary

How does Femasys compare to Lifeward?

Does the media refer more to FEMY or LFWD?

Is FEMY or LFWD more profitable?

Which has preferable valuation and earnings, FEMY or LFWD?

Which has more volatility and risk, FEMY or LFWD?

Do analysts recommend FEMY or LFWD?

Do institutionals & insiders believe in FEMY or LFWD?

Summary

How does Femasys compare to Jin Medical International?

Which has better earnings & valuation, FEMY or ZJYL?

Do analysts recommend FEMY or ZJYL?

Does the media refer more to FEMY or ZJYL?

Which has more risk & volatility, FEMY or ZJYL?

Is FEMY or ZJYL more profitable?

Do insiders & institutionals believe in FEMY or ZJYL?

Summary

How does Femasys compare to Adagio Medical?

Is ADGM or FEMY more profitable?

Which has preferable valuation and earnings, ADGM or FEMY?

Which has more risk & volatility, ADGM or FEMY?

Do analysts prefer ADGM or FEMY?

Does the media prefer ADGM or FEMY?

Do insiders and institutionals believe in ADGM or FEMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools